A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer

Shinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, Ichiro Kawada, Satoshi Yoda, Hideki Terai, Takashi Sato, Kota Ishioka, Daisuke Arai, Keiko Ohgino, Hirofumi Kamata, Jun Miyata, Hiroki Kabata, Tomoko Betsuyaku, Kenzo Soejima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: This Phase II studywas conducted to evaluate the efficacy and safety of S-1 and irinotecan combination therapy as a second-line treatment in patients with advanced non-small cell lung cancer. Methods: Irinotecan was administered at 60 mg/m2 on Days 1 and 8. Oral S-1 was administered on Days 1-14 every 3 weeks at 80 mg/day for patients with a body surface area of <1.25 m2, 100 mg/day for patients with a body surface area of 1.25-1.5 m2 and 120 mg/day for patients with a body surface area of >1.5 m2. The primary endpoint was response rate, while the secondary endpoints were progression-free survival, overall survival and safety. Results: Thirty-one patientswere enrolled in this study. The response and disease control rateswere 6.5 and 58.1%, respectively. Progression-free survival and median survival time were 2.8 and 12.6 months, respectively. Grade 3-4 adverse events were reported for 29.0% of the patients. Hematological toxicities of Grade 3 or 4 included leukopenia (9.7%), neutropenia (9.7%), febrile neutropenia (3.2%), thrombopenia (3.2%) and anemia (6.5%). Non-hematological toxicities of Grade 3 or 4 included pneumonitis (6.5%), diarrhea, colitis, dyspnea, rash, oral mucositis, anorexia and pulmonary thromboembolism/deep vein thrombosis (3.2% each). Conclusions: S-1 and irinotecan combination therapy at the present dose and schedule exhibited only modest efficacy with mild toxicities in previously treated patients with non-small cell lung cancer. No further clinical investigation with current dose and schedules is warranted for patients with non-small cell lung cancer who failed first-line platinum-based doublet chemotherapy.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalJapanese journal of clinical oncology
Volume45
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

Keywords

  • Irinotecan
  • Non-small-cell lung cancer
  • Phase II trial
  • S-1
  • Second line

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this